Trial · NCT04745026
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Aberrant Behavior Checklist (ABC) Subscale Total Scores | Baseline up to Week 12 | Aberrant behavior checklist subscale total scores were assessed in participants with available data in the Full Analysis Set. | score on a scale | MEAN |
| PRIMARY | Change From Baseline in Vineland Adaptive Behavior Scales-3 (VABS-3) Scores | Baseline up to Week 12 | Vineland Adaptive Behavior Scales-3 (VABS-3) scores were assessed in participants with available data in the Full Analysis Set. | score on a scale | MEAN |
| PRIMARY | Number of Patients Per Clinical Global Impression Improvement (CGI-I) Category | Day 85 | Patients per CGI-I category were assessed in participants with available data in the Full Analysis Set. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Change From Baseline in Clinical Global Impression Severity (CGI-S) Scores | Baseline up to Week 12 | CGI-S was assessed in participants with available data in the Full Analysis Set. | score on a scale | MEAN |
| SECONDARY | Number of Participants Reporting Treatment-emergent Adverse Events | Baseline up to Week 12 | Adverse events were assessed in the Safety Analysis Set. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Mean Change From Baseline in Hematology Clinical Laboratory Levels | Baseline up to Week 9 (end of taper/withdrawal) | Hematology clinical laboratory levels were assessed in participants with available data in the Safety Analysis Set. | 10^9 cells/L | MEAN |
| SECONDARY | Mean Percentage Change From Baseline in Hematology Clinical Laboratory Levels | Baseline up to Week 9 (end of taper/withdrawal) | Hematology clinical laboratory levels were assessed in participants with available data in the Safety Analysis Set. | percentage change from baseline | MEAN |
| SECONDARY | Mean Change From Baseline in Hemoglobin Levels | Week 9 (end of taper/withdrawal) | Hemoglobin levels were assessed in participants with available data in the Safety Analysis Set. | g/dL | MEAN |
| SECONDARY | Mean Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin Levels | Week 9 (end of taper/withdrawal) | Erythrocyte mean corpuscular hemoglobin levels were assessed in participants with available data in the Safety Analysis Set. | pg/cell | MEAN |
| SECONDARY | Mean Change From Baseline in Erythrocyte Mean Corpuscular Volume Levels | Week 9 (end of taper/withdrawal) | Erythrocyte mean corpuscular volume levels were assessed in participants with available data in the Safety Analysis Set. | fL | MEAN |
| SECONDARY | Number of Patients With Clinically Significant Vital Sign Values | Post-baseline up to 12 weeks | Vital signs were assessed in participants with available data in the Safety Analysis Set. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients With Clinically Significant Physical Examination Procedure Findings | Baseline up to Day 85 post-baseline | Abnormal physical exam findings were assessed in participants with available data in the Safety Analysis Set. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Patients With Clinically Significant 12-lead Electrocardiogram Findings | Baseline up to Day 85 post-baseline | Clinically significant 12-lead electrocardiogram were assessed in participants with available data in the Safety Analysis Set. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Reporting Suicidal Ideation or Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS) | Baseline up to Day 92 | Suicidal ideation or behavior was assessed in participants with available data in the Safety Analysis Set. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04745026/outcomes